Glyxambi (Empagliflozin/Linagliptin): A Dual-Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes

Podobné jednotky

• Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma
  Autor: Raedler, Lisa A.
  Vydáno: (2015)
• Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting
  Autor: Raedler, Lisa A.
  Vydáno: (2015)
• Aripiprazole Lauroxil (Aristada): Long-Acting Atypical Antipsychotic Injection Approved for the Treatment of Patients with Schizophrenia
  Autor: Raedler, Lisa A.
  Vydáno: (2016)
• Once-Fatal Conditions Have Become Chronic: Early Trends in the FDA's 2015 Approvals
  Autor: Branning, Gary
  Vydáno: (2015)
• Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera
  Autor: Raedler, Lisa A.
  Vydáno: (2015)